Comparative Analysis of Clinical Research Requirements for Oncological Products in India and USA with Emerging AI Applications

Globally, cancer is the leading cause of morbidity and mortality. The incidence of cancer varies by area in India, making prevention and management extremely difficult. India's cancer burden was estimated to be 26.7 million DALYs_AMI in 2021 and is predicted to rise to 29.8 million in 2025. The country's north and northeast had the highest burdens, with 2408 and 2177 DALYs_AMI per 100,000, respectively, and among males. The seven most common cancer sites are lung (10.6%), breast (10.5%), esophagus (5.8%), mouth (5.7%), stomach (5.2%), liver (4.6%), and cervix uteri (4.3%) which accounts for over 40% of the overall cancer burden.^[1]

Similarly, Cancer is also the second leading cause of death in the United States overall and the leading cause among people younger than 85 years. In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. Native American and Black people have two to three times the cancer death rate as White people for numerous cancers, many of which are largely preventable.^[2]

The regulatory landscape for clinical trials is crucial for the development and approval of oncology products. Given the high prevalence of cancer and the continuous need for innovative treatments, understanding the regulatory requirements in major markets like India and the USA is essential for pharmaceutical companies and researchers. The regulatory frameworks in both India and the USA are complex and differ considerably. Understanding these variations is crucial for designing and executing successful clinical trials. Furthermore, regulatory approval in both markets is key to ensuring that new oncology treatments are accessible to a broader patient population. Oncology products represent a significant portion of the pharmaceutical market, contributing around 20% of global pharmaceutical sales. In India, oncology drugs make up roughly 12% of the pharmaceutical market, while in the USA, this figure rises to 25%.

India has increasingly become the preferred destination for clinical trials due to its diverse population and cost-effective trial environment. At the same time, the USA has a more stringent regulatory framework governed by USFDA, still each country ensures patient safety, data integrity, and scientific validity. While several publications discuss general clinical trial processes, this review analyzes and contrasts the regulatory authorities, safety reporting system, ethical oversight mechanisms, approval timelines involved in oncology trial in both countries. The objective is to understand the clinical trial requirements for oncological products in India, to identify the ethical guidelines for conducting cancer clinical trials, to create framework for the clinical trial regulatory approval processes for oncology trials in India and USA, to assess the differences in timelines and documentation requirements for clinical trials in India and USA, this will help researchers, sponsors and regulators in aligning global practices and enhancing the efficiency and ethical conduct of cancer clinical trial .

Drug development for oncology is a difficult, time-consuming, and risky process. Clinical trials frequently encounter difficulties with patient recruitment, trial design, data management, and outcome prediction. Artificial intelligence has become a game-changing tool in the biomedical industry in recent years, providing various ways to optimize different aspects of clinical trials. AI has the ability to greatly increase the development process of cancer drugs, from improving trial monitoring and adaptive designs to improving patient selection through predictive modeling. The use of AI in oncology clinical trials is examined in this review, with an emphasis on how it can boost productivity, cut expenses, and ultimately improve patient outcomes.

DISCUSSION:

Before a drug is offered for sale, it has to be approved, and a clinical trial has to be performed to ensure its safety and effectiveness. For the protection of the safety of the patients and ethical practice of clinical trial, the countries have provided clinical trial regulations, which are to be followed by the concerned organizations.

In terms of Clinical Research, particularly oncology trials, it is essential to understand the key stakeholders and concepts involved.

CLINICAL RESEARCH

“Clinical research” refers to studies, or trials, which are done in people. Clinical research is the key to the discovery of latest diagnostic methods and to develop modern drugs for treatment of diseases. Researchers design clinical trials to answer specific research questions related to a medical product. Before a clinical trial begins, researchers review prior information about the drug to develop research questions and objectives.

Clinical trials follow a typical series from early, small-scale, Phase 1 studies to late-stage, large scale, Phase 4 studies as follows,

Figure 1:Phases of Clinical trial

Phase 1 is termed the non-therapeutic phase,

Phase 2 is called exploratory trial phases,

Phase 3 is known as the therapeutic confirmatory phase, and

Phase 4 is called the post-approval or the post-marketing surveillance phase.^[3]

Phase 0, also called the micro-dosing phase is specially perform for oncology study which  was previously done in animals but now it is carried out in human volunteers to understand the dose tolerability (pharmacokinetics) before being administered as a part of the phase 1 trial among healthy individuals.^[4]

There are three types of Phases 0 clinical trials:

The microdose Clinical trials is used to determine drug pharmacokinetics, to establish pharmacologically relevant doses and to study the mechanisms of action. Micro-dose trials are designed to evaluate pharmacokinetics, bioavailability, metabolism and/or distribution of a drug or its metabolite. This helps to determine the properties of two or more structurally similar analogues aimed at the same molecular target.

The second type of Phase 0 trials determine a dose regimen for molecular targeted compounds or bio-modulators meant for use along with other drugs like conventional chemotherapeutic agents. They do not determine the maximum tolerated dose, but they can be designed to determine a sequence of administration and a dose-range for subsequent combination trials.

The third type of Phase 0 trials, relate the mechanisms of action of drugs to drug efficacy; the pharmacodynamic effect of a drug can thereby be evaluated. It especially holds significance in the field of oncology for the evaluation of molecular targeted chemotherapeutic drugs.^[5]

CLINICAL TRIAL DESIGNS:

“Clinical trial design refers to the framework or methodology used to conduct clinical research in a structured and scientifically valid way”. It defines how a clinical study is planned, including the selection of participants, the intervention or treatment being tested, the controls used for comparison, and the way data is collected and analysed. The primary goal of trial design is to ensure that the study provides reliable results while safeguarding patient safety and minimizing bias.

Clinical research design are of two major types that include non-interventional/observational and interventional/experimental studies. The non-interventional studies may have a comparator group (analytical studies like case-control and cohort studies), or without it (descriptive study). The experimental studies may be either randomized or non-randomized. Clinical trial designs are of several types that include parallel design, crossover design, factorial design, randomized withdrawal approach, adaptive design, superiority design, and non-inferiority design as follows:

1. Parallel Design: - In this study each arm of the study group is allocated a particular treatment (placebo (an inert substance)/therapeutic drug)
2. Crossover Design: - The patient in this trial gets each drug and the patients serve as a control themselves
3. Factorial Design: - Two or more interventions on the participants and the study can provide information on the interactions between the drugs
4. Randomized withdrawal approach Design: - This study evaluates the time/duration of the drug therapy
5. Matched pairs: - Recruit patients with the same characteristics ^[6]

TYPES OF RANDOMIZATIONS IN CLINICAL TRIAL:

In clinical trial Randomization is used to avoid bias, the types of randomizations are as follows:

1. Simple Randomization: - Participants are assigned to a case or a control group based on flipping coin results/computer assignment.
2. Block randomization: - Equal and small groups of both cases and controls
3. Stratified randomization: - Randomization based on the age of the participant and other covariates.
4. Co-variate adaptive randomization/minimization: - sequential assignment of a new participant into group based on the covariates
5. Randomization by body halves or paired organs (split body organs): - one intervention is given to half of the body and comparator is given to other half of body
6. Clustered Randomization: - Intervention is administered to clusters/groups by randomization to prevent contamination and either active or comparator intervention is administered for each group
7. Allocation by randomized consent (Zelen trials): - Patients are allocated to one of the two trial arms ^[6]

CLINICAL TRIAL METHODS: -

The clinical trial methods are as follows:

1. Randomized trial: - Study participants are randomly assigned to a group
2. Open-label: - Both study subjects and the researchers are aware of the drug being tested
3. Blinded (single-blind): - In single-blind studies, the subject has no idea about the group (test/control) in which they are placed
4. Double-blind (double-blind): - In the double-blind study, the subjects as well as the investigator have no idea about the test/control group
5. Triple-Blind: - In the triple-Blind study, the subject, investigator and the data analyst do not have idea about which treatment group participants are within.^[6]

DIFFERENCE BETWEEN ONCOLOGY CLINICAL TRIAL AND OTHER CLINICAL TRIAL: -

Oncology clinical Trial differs from other non-oncology trials in many ways. Most notably, cancer is understood as many diseases, not just one. For instance, types of cancer can include lung cancer, breast cancer, kidney cancer and many more. This makes oncology clinical trials particularly complicated in comparison to other therapeutic areas. The difference is as follows: 

1. Endpoints: -

The endpoints, for oncology clinical trial and other clinical trial differ greatly, for example, rather than running a clinical trial to test the safety and efficacy of an antibiotic against an infection, an oncology trial is trying to extend and improve a subject’s quality of life. The endpoints in oncology clinical trial are overall survival which is considered as the “Gold standard” primary clinical  endpoint, Progression-free survival , Time to progression , Event-Free Survival , Disease-free survival , Time to Treatment Failure , Time to Next Treatment , Duration of Clinical Benefit , Duration of Response, Objective Response Rate , Complete Response, Pathological Complete Response , Disease Control Rate , Clinical Benefit Rate , Health-Related Quality of Life , Milestone survival .^[7]

2. Comparator Drugs: -

In the typical clinical trial process, a placebo is used in place of the treatment to measure the effectiveness of new development therapies in comparison, whereas in case of oncology clinical trial Placebos are never used in place of treatment when an existing standard therapy exists. If a patient is given a placebo in an oncology trial, it is always in conjunction with other approved treatments.

3. Measures of adverse events: -

In non-oncology trials, adverse events are measured as mild, moderate or severe. However, in oncology clinical trials, adverse effects are measured using a unique grading system, which rates events from 1 to 5 depending on severity.

These guidelines are administered by the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE). These oncology-specific guidelines classify adverse events as follows:

• Grade 1 – classifies mild adverse events
• Grade 2 – classifies moderate adverse events
• Grade 3 – classifies severe adverse events
• Grade 4 – assigns life-threatening or disabling adverse events 
• Grade 5 – assigns death-related adverse events

The full criteria may not apply to all adverse events. For example, iron overloads are classified as level 2 adverse events at a minimum, whereas events including tinnitus and vertigo are only classified as high as level 3.

4. Patient recruitment

Patient recruitment is often more of a challenge with oncology trials. Often more sites are needed to meet population requirements which increases costs to the sponsor incrementally. According to Applied Clinical Trials, Lack of participation can cause an oncology trial to recruit slowly, often lengthening the trial's timeline by months or even years.^[8]

ETHICS COMMITTEE:

The Role of ethics committee is to monitor all the protocols of the research study, the informed consent form, and other necessary documents that are related to the research proposal. It is the responsibility of the ethics committee to give approval of the study after reviewing all documents to monitor the study on a daily basis and also maintain the confidentiality of the records. It is the duty of ethics committed to protect the rights and safety of patients involved in study. All records must be maintained for 5 years after completion of the study. This also examines Severe adverse events and report it to DCGI.^[9]

SPONSORS:

“The sponsor has the responsibility for starting, managing and giving financial support to a clinical trial”. The investigator can also play the role of Sponsor. The sponsor can transfer the trial related activity to other CRO or scientific body, but it should be documented in written. The sponsor must have knowledge for conducting trial, it must evaluate the investigator before starting clinical trial. The investigator Brochure must be provided to investigator, and all details of investigator must be verified. It is the responsibility of the Sponsor to obtain approval from DCGI and ethics committee. The sponsor has to submit the Protocol Report, Case Report form and ICF^.[9]

INVESTIGATOR:

The role of investigator is to Conduct and supervise the whole study. The investigator must have the required qualification, experience and training as per the protocol. Before starting the trial, the investigator and sponsor must have agreement on paper signed, monitoring responsibilities etc. The work of investigator is to obtain Informed consent from patients, approval from ethics committee, apart from that any adverse event reported must be reported within the provided time. Investigator cannot take more than three trials at the time.^[9]

CLINICAL TRIALS REGISTRY-INDIA: -

This is free, searchable online site where clinical trial registration can be done which are performed in India. All types of clinical trial can be registered here e.g. Observational data, interventional trial, Phase IV study, etc. These are easy to search and handle by common people from its official page. The World Health Organization reorganize the CTRI as the primary registry in the year 2008, from this year every month data gets transferred from CTRI to the international clinical trials registry site. In year 2009, CDSCO made it compulsory for every clinical trial to be register in CTRI.^[9]

PROTOCOL: -

“Protocol is a document which provide the background, objectives, rationale, design, methodology (including the methods for dealing with adverse events, with­drawals etc.) of the study”. It also provides the criteria in which the study will be performed. The protocol must provide detailed processes for carrying out the trial, to ensure that the personnel coming in contact with the clinical trial collect data as per the laws. If any amendments are to be made in protocol, then it should be notified and approved by CLA, along with approval from Ethics Committee.^[10]

INVESTIGATOR BROCHURE: -

“Investigator Brochure is a collection of data which includes justification for the proposed study for the Investigator consisting of all the clinical as well as non-clinical information available on the Investigational Product known prior to the onset of the trial”.

The IB should include Sponsor’s name, the reference number allocated to the study, the identity of each investigational product (i.e. research number, chemical or approved generic name, and trade name where legally permissible and desired by the sponsor).

The IB should bear an edition number and date. wherever applicable it also bears a reference to the number and date of supersedes version.^[11]

INFORMED CONSENT: -

Informed Consent is an important part of any ethical research work. In all study research written informed consent is to be obtained from each study subject. The subject must be informed verbally about the type of study, risks, benefits etc. in easy language that is understandable to participants. It should be approved by the ethics committee and furnished by the licensing authority. If a person is not able to give informed consent, then a legally authorized representative should provide consent on its behalf.^[12]

APPROVAL PROCESS FOR CONDUCTING CLINICAL TRIAL IN INDIA:

Step 1: Approval from the Drugs Controller General, India.

Step 2: Permission from particular Ethics Committee where the clinical study is designed.

Step 3: Compulsory registration on the ICMR website www.ctri.in. ^[13]

Figure 2:Clinical Trial Approval process in India

APPROVAL PROCESS FOR CONDUCTING CLINICAL TRIAL IN USA:

If the drug from the Preclinical trial is found safe, then Clinical Trial in Humans need to be performed before getting approval for marketing drugs. The Investigational New Drug Application is an application filed to FDA to start clinical trials in the USA. It is the Responsibility of the Sponsor to file Investigational New Drug application. The Food & Drug Administration does not charge any fee to review investigational new drug submissions.^[14]

Figure 3:Clinical trial approval process in USA
COMPARISON CLINICAL TRIAL APPROVAL PROCESS REQUIREMENTS IN INDIA AND USA ^[15]

Table 1:Comparison of Clinical Trial process in INDIA and USA

COMPARISON BETWEEN INSTITUTIONAL ETHICS COMMITTEE AND INSTITUTIONAL REVIEW BOARD:^[15]

Table 2:Comparison between IEC and IRB